

Procedure and Committee business—Cont.**Bills—Cont.****Clause by clause study**

Debate, M. (White), 4:5, 8-9, 15, 18, 24, 38; 5:6, 46-9, agreed to on recorded division, 4

Amdt. (McCurdy), 4:31-4, negated by show of hands, 3

Proceeding, 16:12-3, 20-1; 17:22

Scheduling, 10:46-50; 11:32-4, 80-1; 12:76-7; 15:99-100; 17:43-5

M. (Orlikow), 11:34-8, as amended, agreed to, 4

Amdt. (Tardif), 11:37-8, agreed to, 4

M. (Orlikow), 15:69-70, negated on recorded division, 4

Consideration, expediting, 4:16, 18

Translation, French version inadequate, 1:9-10

Briefs

Deadline, 2:5-7; 4:14-5, 18-9, 24, 38-9; 5:6-7, 47-8

Distribution, in advance, 3:5, 22-3; 10:47; 14:5-6, 33-4

Chairman

Appointment by Speaker, 1:6

Role, 4:12-3

Clerk, role, 4:23**Corrigendum, 17:3; Issue 18**

M. (Bertrand), 17:18, agreed to, 10

M. (Bertrand), 17:18, agreed to, 10

Documents appending to minutes and evidence, M. (Tardif), 10:4, agreed to, 3

Errata, Issue 17

Information, requesting, 3:12, 14, 52-3, 57, 64-5; 6:25, 38; 8:20, 28; 14:37-8

Meetings**Adjourning**

M. (Dingwall), 4:34, negated by show of hands, 4

M. (White), 4:41, agreed to

Reconvening after vote, 6:60

Scheduling, 1:41-3; 15:100

M. (White), 4:5, 8-10, 16, 37; 5:6, 46-9, agreed to on recorded division, 4

Time limits, 16:10-1

Members

Minority rights, 4:9, 14, 19

Privileges, breaching, 9:5-6, 8-10, 22

M. (Dingwall), 9:23, negated on recorded division, 3

Membership, changes, 3:68; 4:18

Minister, inviting, 1:8-10

Motions

Notice, 8:31-4

Standing, 5:8-9

Organization meeting, 1:6-10

Printing, minutes and evidence, M. (Kempling), 1:7-8, agreed to, 4

Proceedings, broadcasting, M. (Dingwall), 5:9-10, out of order,

Chairman's ruling, 3

Questioning of witnesses

Order of questioners, 3:36-7, 39, 52

Time limit, 3:25-6; 6:11-2

Quorum, meeting and receiving/printing evidence without, 1:6-7

M. (Kempling), 1:7, agreed to, 4

Staff, hiring, M. (Kempling), 8:30, agreed to, 3

Steering committee *see* Procedure and Committee business—Agenda and procedure subcommittee

Travel

Authorization, 2:5-6

Scheduling, 1:10

Procedure and Committee business—Cont.**Witnesses****Appearances**

Restricting, 8:29-30; 9:5-6

Scheduling, 2:5-7; 5:49; 8:49; 9:9-10, 22, 40-1; 10:47-8, 50

M. (Orlikow), 15:69-70, negated on recorded division, 4

Time limit, M. (White), 4:5-21, 23-4, 34-41; 5:5-6, 46, 49; 6:9-10, agreed to on recorded division, 5:4

Amdt. (Kempling), 4:25-8, agreed to, 3

Amdt. (McCurdy), 4:28-31, out of order, Chairman's ruling, 3

Expenses, Committee paying, 2:6; 7:7, 19

M. (Tardif), 1:8, agreed to, 4

Inviting, 3:39; 10:20, 46; 14:5-6, 76-8; 15:70

M. (White), 8:29, 31-4; 9:5-9, agreed to, 8:3

Progressive Conservative Party *see* Drugs Prices Review Board;

Health care—Canada Health Act policy co-ordinating;

Pharmaceutical Manufacturers Association of Canada

Protegez-vous magazine *see* Drugs and

pharmaceuticals—Costs/prices, Comparison shopping

Provinces

Legislation, Bill C-22 position, 1:37-8, 43

Social services/research and development declining, Bill C-22 effect, 6:63

See also Atlantic provinces; Cystic fibrosis; Drug plans; Drug Prices

Review Board; Drugs and pharmaceuticals; Eastman report;

National Federation of Nurses Unions—Background; Patent

Act (amdt.) (Bill C-22)—References, Andre consultations

Public Service Alliance of Canada

Group Surgical-Medical Insurance Plan participation, Bill C-22

costs increasing/benefits eroding, 10:23-6

Political/union affiliations, 10:28, 32

See also Witnesses

Puerto Rico *see* Drugs and pharmaceuticals industry—Research and

development, Employment

Quality control *see* Generic drugs—Research and development,

Clinical research vs quality control only

Quebec *see* Abbot Laboratories; Boehringer Ingelheim; Drug plans;

Drugs and pharmaceuticals industry; Health

care—Drugs—Hospitals; Hoffman-La Roche Limited

Quebec Federation of Senior Citizens

Andre letter, Bill C-22 supporting, 1:36; 12:17; 15:66

Background, 12:20, 26-7

Members' survey, 12:17-8, 27; 15:66

See also Witnesses

Ranitidine *see* Drugs and pharmaceuticals—Tagamet/cimetidine

Redling, George (Consumer and Corporate Affairs Department)

Patent Act (amdt.) (Bill C-22), 16:3, 7, 77-9, 81-2; 17:10, 28-9, 31-2, 40-1

Regulation 2900 *see* Brand name drugs—Exclusivity period from

imports, Contractual obligations

Regulations and Other Statutory Instruments Standing Joint**Committee**

Letter *re* Bill C-22, 16:32-3

Report to House, 17:4-9

Revised, 18:3-8